valu usd unless otherwis note
fda approv aimovig rais price target
view aimovig expect fda approv came yearli price
anticip could improv reimburs bolster amgn/
nv lead within cgrp class rais pt account
takeaway today fda approv aimovig prevent
treatment migrain pdufa date approv
expect disclos annual price well
expect recent kol feedback expect
even price cite icer recent report
see anticip lower-than-expect price reflect
extens payer discuss amgn/nv like engag
order potenti obtain broad/favor formulari access
potenti mitig impact contract strategi competitor
line appear repres amgn/nv move forward
price-consci manner potenti repres lesson
learn experi increas market
penetr estim aimovig migrain
market result increas price target host
confer call tomorrow may et discuss approv
launch look color regard reimburs
model chang updat model reflect fda approv
increas po addit lower price
assumpt reflect yearli price announc
increas aimovig market penetr estim
given price allow broad access peak ww sale estim
aimovig vs previous chang result
sh increas price target
appear set take advantag aimovig first-mov
advantag recal lead recent increas given teva
disclosur fremenezumab june approv launch
expect delay ye earliest exact time uncertain
earn call manag note sale infrastructur
place pois opportunist take lead
set price class clearli reflect aimovig
yearli price addit specif outlin pr
manag note intent negoti payer value-
base reimburs contract note line recent
pbm commentari addit amgn/nv alreadi begun initi
conversations/relationship potenti prescrib conduct
diseas educ presentations/seminar look detail color
regard initi tomorrow confer call
dissemin may produc may price prior trade day market close estimate unless otherwis note
capit market appreci consider institut investor all-america research survey
see limit forward growth emerg
pipelin yet fill shoe amgn matur product
eros see inexpens biotech compani
rel basi like dividend perspect
steadi cash flow despit headwind base busi
despit see risk amgn recent near-
term product launch cgrp humira biosimilar
upsid slower product eros remain
sidelin
biosimilar remain major part valuationw see
amgn intern pipelin biosimilar major revenu
ep driver though remain slightli cautiou
street launch time view recent setback
humira biosimilar indic challeng launch
environ initi anticip model amgn
biosimilar launch remicad rituxan avastin
herceptin humira see launch ahead
upsid model
launch repatha upcom
focu emerg pipelin becom construct
launch
omecamtiv parsabiv key driver off-set base busi
eros see repatha uptak signific driver
close monitor rx share follow posit long-
risk greater-than-expect competit core
busi franchis lower-than-expect uptak
grow busi develop regulatori setback
bloomberg capit market estim upside/downside/target
valu dcf basi use wacc
termin growth rate view trade
appropri valu forward price-to-earnings basi vs peer similar
growth prospect discount project revenu
risk-adjust revenu pipelin product contribut
sh revenu contribut cash contribut
result price target support
sector perform rate
upsid scenario assum longer-than-
expect delay entranc biosimilar
market slower-than-expect revenu eros
base busi higher-than-expect uptak repatha
downsid scenario assum faster
expect market entri biosimilar lead greater
market share eros price pressur
base busi regulatory/litig setback
biosimilar franchis continu slow uptak repatha
first-mov advantag could enabl aimovig captur half crgp market
physician commentari doc day see nyc day boston day takeaway
indic first-to-market enabl aimovig captur major new patient
start given wait list amass hundr interest preval patient bolu could
enabl aimovig lock meaning proport address popul
reluct switch ahead competitor entri doc check indic favor
dynam could result aimovig captur cgrp market repres
upsid revis stabl assumpt competitor enter
valu dcf basi use wacc termin growth rate
view trade appropri valu forward price-to-earnings basi vs peer
similar growth prospect discount project revenu market product
contribut discount risk-adjust revenu pipelin product contribut
revenu contribut cash contribut result
sh price target support sector perform rate
risk rate price target
factor neg influenc valuat rate greater-than-expect
competit core busi franchis lower-than-expect uptak
grow busi develop regulatori setback late-stag pipelin
global biotechnolog compani focus develop manufactur
commerci novel biotherapeut primarili cancer nephrolog inflammatori
diseas cardiovascular diseas bone diseas pioneer use
recombin dna produc world success blockbust biotech drug
compani core busi erythropoietin epo stimul agent esa
epogen aranesp neutrophil stimul neulasta franchis
obtain princip inflammatori diseas busi enbrel acquisit
immunex go forward compani primari futur growth driver repatha
compani report capit market estim
chang model revenu expens mm expens mm expens mm incom mm incom mm incom mm non-gaap ep exhibit incom statement
compani report capit market estim
incom product total product product product cost expens non oper incom ebit non tax tax net ep ep exhibit dcf valuat
compani report capit market estim
discount rate equiti growth rate mm except per-shar data discount add add effect add termin biotechnolog
